Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 26, 2009

Affymetrix and Beckman Coulter Ally to Provide Automated Target-Prep Solutions

  • Affymetrix and Beckman Coulter plan on offering researchers co-developed products that provide optimized, robust solutions and end-to-end support for genomic research. This platform will provide researchers with standardized systems that include all components necessary to run Affymetrix genotyping and gene-expression assays.

    The goal of the partnership is to yield an expanding list of Affymetrix-validated automated target-preparation methods, developed on an Affymetrix-specific configuration of Beckman Coulter’s Biomek FXp Dual Arm Multichannel with Span 8 Liquid Handler.

    Major benefits will include the flexibility to process samples using Affymetrix GeneChip® Arrays or Array Plates with a single method, user friendly interface, rapid implementation of new methods, a validated platform, elimination of costly mistakes, and delivery of high-quality results, the firms report.

    “Beckman Coulter’s long history in manufacturing quality automation platforms with proven reliability make the company the ideal partner for developing automated target-prep assays,” comments Kevin King, president and CEO of Affymetrix. “These products not only provide a much needed target-prep solution for our large installed base of GeneChip Array cartridge users, but very importantly, this agreement aligns with our strategic goals to re-engineer the Affymetrix platform. With automated target-prep robotics in front of our GeneTitan™ System, our customers will benefit from walk-away automation from prepared samples all the way through array processing and data generation.”

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »